Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atropine 0.025% insertion fluid added to orthokeratology for childhood myopia
ACTRN12620001046998Phase 3Withdrawn
- Sponsor
- The University of Auckland
- Start
- Jan 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atropine in myopia (2 arms), sponsored by The University of Auckland. Primary endpoints: Change in axial eye length at 36 months and Change in refractive error at 36 months. Planned start Jan 2021; status: withdrawn.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on ACTRN12620001046998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001046998.